The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
May 2nd 2024
This month in review highlights top coverage of the latest news in nephrology, ranging from new clinical trial data in IgAN to research about kidney disease management.
Navigating Newer Approaches to Managing IgA Nephropathy
April 14, 2024
Register Now!
New York GU™ 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Expert Illustrations and Commentaries™: Emerging Therapies and Treatment Strategies to Improve Care for Your Patients with Anemia in CKD
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma
View More
Medical Crossfire®: Optimizing Care for Patients With Anemia and Chronic Kidney Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Clinical Decision Support System May Aid Hypertension Management, Improve Clinical Outcomes in CKD
March 15th 2024Patients whose primary care practitioners were randomized to a clinical decision support system intervention achieved a statistically significant reduction in SBP versus usual care but had similar rates of BP control.
In-Center Hemodialysis Patient Outcomes Negatively Impacted by Patient Care Technician Understaffing
March 12th 2024A greater patient-to-patient care technician ratio was associated with increased mortality and hospitalization with lower rates of waitlisting and transplantation among patients receiving in-center hemodialysis.
Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial
March 5th 2024Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.
Experts' Perspectives: How Lacking Clinical Trial Diversity Impacts Public Health
March 1st 2024This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.